Final Report on Low-Dose Estramustine Phosphate (EMP) Monotherapy and Very Low-Dose EMP Therapy combined with LH-RH Agonist for Previously Untreated Advanced Prostate Cancer

Abstract

Purpose: In order to assess the efficacy and toxi­city of oral estramustine phosphate (EMP) administration, low-dose EMP monotherapy (study 1) and very low-dose EMP therapy with luteinizing hormone-releasing hormone (LH-RH) agonist (study 2) were conducted in previously untreated prostate cancer and long-term outcomes were compared between the 2 study groups. Materials and Methods: Studies 1 and 2 were independently performed beginning in June 1999 and November 2001, respectively. Study 1 was composed of 87 patients including 85 assessable patients. All 108 patients recruited for study 2 were assessable. Low-dose EMP monotherapy (2 capsules / day or 280 mg / day) was used in study 1 and very low-dose EMP (1 capsule / day or 140 mg / day) combined with LH-RH agonist was adopted in study 2. Results: Overall prostate specific antigen (PSA) ­response rates in studies 1 and 2 were 92.3 % and 94.2 %, respectively, and overall toxicity rates were 54.1 % and 38.9 %, respectively. EMP discontinuation due to side effects was encountered more often in study 1 (45.9 %) than in study 2 (27.8 %). Among the adverse side effects gastrointestinal toxicity was most prevalent in both studies. One patient died of acute pulmonary embol­ism in study 1, but no one died in study 2. There were 6 cancer deaths in the gastrointestinal tract in study 1 but only 2 cancer deaths in study 2. Conclusion: Our data indicate that the overall PSA response rate was comparable between both studies. However, rates in overall toxicity and drug discontinuation were higher in study 1 than in study 2. We consider that study 2 is more promising for the treatment of previously untreated advanced prostate cancer, although the rate of adverse side effects is still high as compared with other hormonal therapies. In order to overcome the high toxicity rate, especially the gastrointestinal toxicity, we recently elaborated a method ­employing tailor-made medicine using SNPs of 1A1 gene in cytochrome P-450 for decreasing the rate of gastrointestinal toxicity. Using this method of patient selection, study 3 has been successfully launched on September 2005 with high drug compliance. Better clinical results are being accumulated. 

Key words

low-dose EMP monotherapy - very low-dose EMP with LH-RH agonist - previously untreated prostate cancer - advanced prostate cancer - estramustine phosphate

References

• 1 Smith D C. Chemotherapy for hormone refractory prostate cancer.  Urologic Clinics of North America. 1999;  26 323-331
• 2 Perry C M, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.  Drugs Aging. 1995;  7 49-74
• 3 Olmstead J. Microtubule associated proteins.  Ann Rev Cell Biol. 1986;  2 419-455
• 4 Van Poppel H, Baert L. The present role of estramustine phosphate in advanced prostate cancer. In: European Organization for Research and Treatment of Cancer. Genitourinary Group Monograph 10 – Uro­logical Oncology: Reconstructive Surgery, Organ Conservation, and Restoration of Function. Hoboken, NJ: Wiley-Liss, Inc; 1991: 323–341
• 5 Hudes G. Estramustine-based chemotherapy.  Semin Urol Oncol. 1997;  15 13-19
• 6 Pienta K J, Fisher E I, Eisenberger M A et al. A Phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).  Prostate. 2001;  46 257-261
• 7 Kelly W K, Curley T, Slovin S et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.  J Clin Oncol. 2001;  19 44-53
• 8 Petrylak D P, Macarthur R B, O'Connor J et al. Phase 1 trial of docetaxel with estramustine in androgen-independent prostate cancer.  J Clin Oncol. 1999;  17 958-967
• 9 Kitamura T, Nishimatsu H, Hamamoto T et al. EMP combination che­motherapy and low-dose monotherapy in advanced prostate cancer.  Expert Rev Anticancer Ther. 2002;  2 59-71
• 10 Andersson L, Berlin T, Boman J et al. Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study.  Scand J Urol Nephrol. 1980;  55 143-145
• 11 Benson R CJr, Gill G M. Estramustine phosphate compared with diethylstilbestrol: a randomized, double-blind, crossover trial for stage D prostate cancer.  Am J Clin Oncol. 1986;  9 341-351
• 12 Hauchecorne J. French multicentre study on the use of estramustine phosphate versus diethylstilbestrol. In: Prostate Cancer, Part B: Imaging Techniques, Radiotherapy, Chemotherapy and Management Issues. Alan R. Liss Inc; 1987: 229–234
• 13 Kuss R, Khoury S, Richard F et al. Estramustine phosphate in the treatment of advanced prostatic cancer.  Brit J Urol. 1980;  52 29-33
• 14 Smith P H, De Pauw M, Robinson M EORTC Urological Group et al. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.  Urology. 1984;  6 (suppl) 64-68
• 15 The Leuprolide Study Group . Leuprolide versus diethylstilbestrol for metastatic prostate cancer.  N Engl J Med. 1984;  311 1281-1286
• 16 Tyrrell C J, Altwein J E, Klippel F et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue Goserelin Acetate alone and with Flutamide in the treatment of advanced prostate cancer.  J Urol. 1991;  146 1321-1326
• 17 Gunnarsson P O, Davidsson T, Andersson S-B et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food.  Eur J Clin Pharmacol. 1990;  38 189-193
• 18 Kitamura T. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer.  Int J Urol. 2001;  8 33-36
• 19 Kitamura T, Nishimatsu H, Suzuki M et al. Dual interim report of low-dose Estramustine Phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.  J Applied Res in Clin Experimet Therapeut. 2005;  5 331-344
• 20 Takayasu H, Shida K, Momose S et al. Clinical study on the treatment of prostatic carcinoma with Estracyt.  The Nishinihon J Urol. 1980;  42 715-731
• 21 Takenaka I, Soramoto S, Kagawa S et al. Multicenter randomized clinical trial comparing estracyt mono-therapy with combined androgen blockade therapy (CAB) in the treatment of advanced prostate cancer.  The Nishinihon J Urol. 2001;  63 1-9
• 22 Saito S, Nakajima J, Nakajima Y et al. Clinical efficacy of Leuprolide Acetate and combined treatment with Estramustine for advanced prostate cancer.  Jpn J Urol. 2001;  92 682-693
• 23 Iversen P, Christensen M G, Friis E et al. A phase III trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.  Cancer. 1990;  66 (5 suppl) 1058-1066
• 24 Eisenberger M A, Blumenstein B A, Crawford E D et al. Bilateral orchi­ectomy with or without Flutamide for metastatic prostate cancer.  N Engl J Med. 1998;  339 1036-1042
• 25 Fourcade R O, Cariou G, Coloby P et al. Total androgen blockade with ­Zoladex plus Flutamide vs. Zoladex alone in advanced prostatic carcinoma: Interim report of a multicenter, double-blind, placebo-controlled study.  Eur Urol. 1990;  18 (suppl 3) 45-47
• 26 Mohammed R, Suzuki M, Takahashi S et al. Incidence of gastrointestinal toxicity during estramustine phosphate therapy for prostate cancer is associated with the single-nucleotide polymorphisms in the cytochrome P450 1A1 (CYP1A1) gene.  Cancer Therapy. 2005;  3 525-530